Treatment with tirofiban for acute coronary syndrome (ACS): A systematic review and network analysis

Current Medical Research and Opinion

Volumn 28, Issue 3, 2012, Pages 351-370

  Lang, S H ^a   Manning, N ^a   Armstrong, N ^a   Misso, K ^a   Allen, A ^a   Di Nisio, M ^a,b   Kleijnen, J ^a,c  

^a KLEIJNEN SYSTEMATIC REVIEWS LTD   (United Kingdom)

^b UNIVERSITY OF CHIETI   (Italy)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Acute coronary syndrome; Aggrastat; Systematic review; Tirofiban

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; HEPARIN; HIRULOG; PLACEBO; TICLOPIDINE; TIROFIBAN;

ACUTE CORONARY SYNDROME; BLEEDING; BOLUS INJECTION; DATA BASE; DRUG EFFICACY; HUMAN; LOW DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TREATMENT OUTCOME; TYROSINE;

EID: 84858267976     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.657299     Document Type: Review

References (75)

1. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists: What are the relevant issues concerning their pharmacology and clinical use? Circulation 1999;100:437-44
2. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent STsegment elevation: The task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054
3. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2008;29:2909-45
4. Puddu PE, Siartiti M, Bugiardini R. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes undergoing PCI: A long way to select optimal agent and route. ISRN Vasc Med 2011:doi:10.5402/2011/141430
5. Valgimigli M, Biondi-Zoccai G, Tebaldi M, et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: A meta-analysis of randomized trials. Eur Heart J 2010;31:35-49
6. Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies [Internet]. In: Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions, Chapter 8, Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: Http://www.cochrane- handbook.org [Last accessed 30 August 2011]
7. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in metaanalyses. BMJ 2003;327:557-60
8. Song F, Loke YK, Walsh T, et al. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: Survey of published systematic reviews. BMJ 2009;338:b1147
9. Wells GA, Sultan SA, Chen L, et al. Indirect evidence: Indirect treatment comparisons in meta-analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009. Available at: Http://www.cadth.ca/media/pdf/H0462- itc-tr-e.pdf [Last accessed 14 September 2011]
10. Spiegelhalter D, Thomas A, Best N, et al. WinBUGS User Manual. Version 1.4 [Internet]. Cambridge: MRC Biostatistics Unit, 2003. Available at: Http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/manual14.pdf [Last accessed 31 August 2011]
11. Bhattacharya R, Pani A, Dutta D, et al. Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: An East Indian perspective. Singapore Med J 2010;51:558-64
12. ten Berg JM, van't Hof AWJ, Dill T, et al. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome. J Am Coll Cardiol 2010;55:2446-55
13. Theroux P. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97
14. Valgimigli M, Campo G, de Cesare N, et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: Results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 2009;119:3215-22
15. Van't Hof AWJ, Ten Berg J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): A multicentre, double-blind, randomised controlled trial. Lancet 2008;372:537-46
16. Yan Z, Zhou Y, Zhao Y, et al. Efficacy and safety of tirofiban in high-risk patients with non-ST-segment elevation acute coronary syndromes. Clin Cardiol 2009;32:E40-4
17. Fu XH, Hao QQ, Jia XW, et al. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction. Chin Med J 2008;121:522-7
18. Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: The ADVANCE Trial. J Am Coll Cardiol 2004;44:14-19
19. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997;96:1445-53
20. Gibson CM, Goel M, Cohen DJ, et al. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. J Am Coll Cardiol 1998;32:28-34
21. Juergens CP, White HD, Belardi JA, et al. A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement. Clin Ther 2002;24:1332-44
22. Okmen E, Cam N, Erdinler I, et al. Effects of glycoprotein IIb/IIIa inhibition on QT dispersion in patients with unstable angina and non-Q-wave myocardial infarction. Int J Angiol 2002;11:144-9
23. Cohen M, Gensini GF, Maritz F, et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): A randomized trial. J Am Coll Cardiol 2003;42:1348-56
24. Leoncini M, Toso A, Maioli M, et al. Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study. Am Heart J 2005;150:401
25. Ivandic BT, Kurz K, Keck F, et al. Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes. Thromb Haemost 2008;100:648-54
26. Kim JH, Jeong MH, Rhew JY, et al. Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome. Circ J 2005;69:159-64
27. Martinez-Rios MA, Rosas M, Gonzalez H, et al. Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction. Am J Cardiol 2004;93:280-7
28. Shen J, Zhang Q, Zhang RY, et al. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis 2008;19:271-7
29. Song Y. Evaluation on the safety and efficacy of tirofiban in the treatment of acute coronary syndrome. J Huazhong Univ Sci Technol Med Sci 2007;27:142-4
30. Xianghua F, Qingqing H, Weize F, et al. The effect and safety of tirofiban combined clopidogrel in AMI patients with PCI via transradial approach. Paper presented at World Congress of Cardiology Scientific Sessions; 16-19 June 2010; Beijing, China. Circulation 2010;122:e68
31. Li N, Zu XL, Yan HB. [Tirofiban in percutaneous coronary intervention of patients with acute non-ST segment elevation myocardial infarct: Safety and efficacy]. Acad J Second Mil Med Univ 2007;28:524-6
32. Peng J-j, Ma Z-m, Ren L-h, et al. [Effect of tirofiban in acute anterior myocardial infarction patients without ST segment resolution after primary percutaneous coronary intervention]. Chin J Cardiol 2009;37:725-8
33. Ernst NM, Suryapranata H, Miedema K, et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004;44:1187-93
34. Danzi GB, Sesana M, Capuano C, et al. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am J Cardiol 2004;94:35-9
35. Moliterno DJ, TENACITY Steering Committee and Investigators. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: The tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. Catheter Cardiovasc Interv 2011;77:1001-9
36. Marzocchi A, Manari A, Piovaccari G, et al. Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: Results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial. Eur Heart J 2008;29:2972-80
37. Moliterno DJ, Yakubov SJ, DiBattiste PM, et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: The TARGET follow-up study. Lancet 2002;360:355-60
38. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-94
39. Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: The MULTISTRATEGY randomized trial. JAMA 2008;299:1788-99
40. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903
41. Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003;42:1879-85
42. Cox DA, Stone GW, Grines CL, et al. Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC Trial). Am J Cardiol 2006;98:331-7
43. Mehilli J, Kastrati A, Schulz S, et al. Abciximab in patients with acute STsegment- elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: A randomized double-blind trial. Circulation 2009;119:1933-40
44. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66
45. Tcheng JE, Kandzari DE, Grines CL, et al. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2003;108:1316-23
46. Lincoff AM, Califf RM, Anderson KM, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1997;30:149-56
47. Simoons ML. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-35
48. Califf RM. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61
49. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. The EPIC Investigators. Lancet 1994;343:881-6
50. Miller JM, Smalling R, Ohman EM, et al. Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Am J Cardiol 1999;84:779-84
51. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial. Lancet 2001;357:1915-24
52. Berkowitz SD, Sane DC, Sigmon KN, et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. J Am Coll Cardiol 1998;32:311-19
53. Brener SJ, Barr LA, Burchenal JEB, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998;98:734-41
54. Kastrati A, Mehilli J, Neumann F-J, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 randomized trial. JAMA 2006;295:1531-8
55. Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med 1999;341:319-27
56. Nakagawa Y, Nobuyoshi M, Yamaguchi T, et al. Efficacy of abciximab for patients undergoing balloon angioplasty: Data from Japanese evaluation of c7E3 Fab for elective and primary PCI organization in randomized trial (JEPPORT). Circ J 2009;73:145-51
57. Petronio AS, Musumeci G, Limbruno U, et al. Abciximab improves 6-month clinical outcome after rescue coronary angioplasty. Am Heart J 2002;143:334-41
58. Van den Brand MJBM, Simoons ML, De Boer MJ, et al. Antiplatelet therapy in therapy-resistant unstable angina. A pilot study with REO PRO (c7E3). Eur Heart J 1995;16(Suppl. L):36-42
59. The EPISTENT Investigators. Randomised placebo-controlled and balloonangioplasty- controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92
60. Zeymer U, Margenet A, Haude M, et al. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: Results of the EVA-AMI Trial. J Am Coll Cardiol 2010;56:463-9
61. Durand E, Hamm CW, Macaya CM, et al. A randomised controlled trial of upstream administration of eptifibatide in patients presenting non-ST segment elevation acute coronary syndrome treated with an invasive strategy. EuroIntervention 2007;3:228-34
62. Harrington RA. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43
63. Kleiman NS. Primary and secondary safety endpoints from IMPACT II. Am J Cardiol 1997;80(4 A):29-33B
64. Le May MR, Wells GA, Glover CA, et al. Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: A safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST). Circ Cardiovasc Interv 2009;2:330-8
65. Ohman ME, Kleiman NS, Gacioch G, et al. Combined accelerated tissueplasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: Results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997;95:846-54
66. Momtahen M, Abdi S, Javadzadeh F, et al. Platelet GP IIb/IIIa receptor inhibition by eptifibatide in non ST-elevation MI-acute coronary syndrome. Iran Cardiovasc Res J 2009;3:86-90
67. Ronner E, Van Kesteren HAM, Zijnen P, et al. Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction: A phase II dose escalation, randomized, doubleblind study. Eur Heart J 2000;21:1530-6
68. Tcheng JE. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-8
69. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation 1995;91:2151-7
70. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, June 2008, 80p
71. Song F, Harvey I, Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol 2008;61:455-63
72. Bosch X, Marrugat J, Sanchis J. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. Cochrane Database of Systematic Reviews: Reviews 2010 Issue 9. Art. No.: CD002130. DOI: 10.1002/14651858.CD002130.pub2
73. Ottani F, La Vecchia L, De Vita M, et al. Comparison by meta-analysis of eptifibatide and tirofiban to abciximab in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 2010;106:167-74.e1
74. Dong L, Zhang F, Shu X. Early administration of small-molecule glycoprotein IIb/IIIa inhibitors before primary percutaneous coronary intervention for STelevation myocardial infarction: Insights from randomized clinical trials. J Cardiovasc Pharmacol Ther 2010;15:135-44
75. Lincoff MA, Califf R, Anderson KM, et al. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96